
Orgenesis ORGS
Annual report 2024
added 03-26-2026
Orgenesis Total Shareholders Equity 2011-2026 | ORGS
Annual Total Shareholders Equity Orgenesis
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -37.5 M | -21 M | 27.6 M | 38.5 M | 52.6 M | 5.48 M | 28.4 M | 14.1 M | 12.5 M | -6.44 M | -2.98 M | -2.03 M | -281 K | -82.7 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 52.6 M | -37.5 M | 7.77 M |
Quarterly Total Shareholders Equity Orgenesis
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -23.9 M | -15.5 M | -27.7 M | -21 M | -15.4 M | -12.7 M | 9.99 M | 27.6 M | 30.2 M | 31.8 M | 34.9 M | 38.5 M | 43.3 M | 51.5 M | 54.5 M | 52.6 M | 52.6 M | 52.6 M | 52.6 M | 5.48 M | 5.48 M | 5.48 M | 5.48 M | 26.1 M | 28.4 M | 28.4 M | 26.1 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 12.5 M | 10.6 M | 10.6 M | 10.6 M | -6.44 M | -6.44 K | -6.44 K | -6.44 K | -2.98 M | -2.98 M | -2.98 M | -2.98 M | -2.04 M | -2.03 M | -2.03 M | -2.03 M | -281 K | -281 K | -281 K | -281 K | -82.7 K | -82.7 K | -82.7 K | -82.7 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 54.5 M | -27.7 M | 11.3 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
5.1 M | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
24.3 M | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M | ||
|
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B | ||
|
AstraZeneca PLC
AZN
|
48.7 B | - | - | $ 96.9 B | ||
|
Athira Pharma
ATHA
|
27.8 M | - | - | $ 269 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
-14.6 M | - | 0.74 % | $ 768 M | ||
|
Galera Therapeutics
GRTX
|
3.97 M | - | -32.59 % | $ 7.61 M | ||
|
Midatech Pharma plc
MTP
|
11.4 M | - | -18.52 % | $ 27.3 M | ||
|
Esperion Therapeutics
ESPR
|
-302 M | $ 3.14 | 0.32 % | $ 653 M | ||
|
Eton Pharmaceuticals
ETON
|
26.2 M | $ 35.52 | 3.11 % | $ 956 M | ||
|
Forte Biosciences
FBRX
|
61 M | $ 21.7 | 6.84 % | $ 281 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
69.5 M | - | - | $ 231 M | ||
|
Celyad Oncology SA
CYAD
|
4.32 M | - | - | $ 12.5 M | ||
|
Berkeley Lights
BLI
|
142 M | - | -7.31 % | $ 87 M | ||
|
Generation Bio Co.
GBIO
|
86.2 M | - | - | $ 344 M | ||
|
IMV
IMV
|
-6.6 M | - | - | $ 13.1 M | ||
|
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | ||
|
BioNTech SE
BNTX
|
19.2 B | $ 91.61 | 1.38 % | $ 22.1 B | ||
|
Grifols, S.A.
GRFS
|
8.61 B | $ 8.15 | -0.55 % | $ 5.54 B | ||
|
Autolus Therapeutics plc
AUTL
|
178 M | $ 1.67 | 3.09 % | $ 444 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M | ||
|
Heron Therapeutics
HRTX
|
14.3 M | $ 0.88 | 3.99 % | $ 147 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
6.84 M | - | -4.36 % | $ 27 M | ||
|
Compugen Ltd.
CGEN
|
103 M | $ 2.66 | -1.85 % | $ 249 M | ||
|
Anika Therapeutics
ANIK
|
143 M | $ 15.15 | 0.07 % | $ 217 M | ||
|
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | ||
|
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
5.59 M | $ 3.41 | 2.71 % | $ 5.61 M | ||
|
AIkido Pharma
AIKI
|
69.4 M | - | 1.93 % | $ 17.4 M | ||
|
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | ||
|
Coherus BioSciences
CHRS
|
61 M | $ 1.59 | 5.43 % | $ 186 M | ||
|
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
78.8 M | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
78.8 M | - | - | $ 28.6 M | ||
|
Arcutis Biotherapeutics
ARQT
|
189 M | $ 20.95 | 2.34 % | $ 2.67 B | ||
|
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M |